

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Diffuse large B cell lymphoma (DLBCL)	Enhancer of zeste homolog 2 (EZH2)	<i>In vitro</i> studies identified an EZH2 inhibitor that could help treat DLBCL. <i>In vitro</i> , the lead compound EI1 inhibited EZH2 with an IC ₅₀ value of about 10 nM and about 90-fold specificity for EZH2 over the related enzyme EZH1. In DLBCL cell lines carrying mutant <i>EZH2</i> , EI1 inhibited cell growth at low micromolar concentrations. Next steps could include additional preclinical studies of EI1 in mouse models of cancer. SciBX 6(1); doi:10.1038/scibx.2013.7 Published online Jan. 10, 2013	Patent and licensing status undisclosed	Qi, W. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Dec. 10, 2012; doi:10.1073/pnas.1210371110 Contact: En Li, Novartis Institutes for BioMedical Research, Shanghai, China e-mail: en.li@novartis.com